Art. -Nr.: HY-N0255

alpha-Hederin

(Synonyms: α-Hederin)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

alpha-Hederin (α-Hederin), a monodesmosidic triterpenoid saponin, exhibits promising antitumor potential against a variety of human cancer cell lines. alpha-Hederin could inhibit the proliferation and induce apoptosis of gastric cancer accompanied by glutathione decrement and reactive oxygen species generation via activating mitochondrial dependent pathway.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.10%
CAS. Nr.: 27013-91-8
Formel: C₄₁H₆₆O₁₂
Molecular Weight:750.96

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

alpha-Hederin Chemical Structure

CAS. Nr.: 27013-91-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	12.29 μM Compound: 12a	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
A549	IC₅₀	15.3 μM Compound: 1, PSA	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 25958248]
A549	IC₅₀	28 μM Compound: 24	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
A549	IC₅₀	33 μM Compound: 24	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
Bel-7402	IC₅₀	13.2 μM Compound: 1, PSA	Cytotoxicity against human Bel7402 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 25958248]
DLD-1	IC₅₀	38 μM Compound: 24	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
DLD-1	IC₅₀	60 μM Compound: 24	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
ECV-304	IC₅₀	29 μM Compound: alpha-hederin	Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry	[PMID: 22503361]
ECV-304	IC₅₀	29 μM Compound: Alpha-hederin	Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay	[PMID: 24084294]
ECV-304	IC₅₀	35 μM Compound: alpha-hederin	Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay	[PMID: 22503361]
ECV-304	IC₅₀	35 μM Compound: Alpha-hederin	Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay	[PMID: 24084294]
HeLa	IC₅₀	21.18 μM Compound: 12a	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HepG2	IC₅₀	16.34 μM Compound: 12a	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HepG2	IC₅₀	5.5 μM Compound: 8	Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay	[PMID: 21870831]
HL-60	IC₅₀	11.78 μM Compound: 12a	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HL-60	IC₅₀	7.1 μg/mL Compound: 2	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 10514313]
HL-60	IC₅₀	7.1 μg/mL Compound: page 1228, R18C1	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 11575962]
L02	IC₅₀	11.5 μM Compound: 1, PSA	Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 25958248]
L02	IC₅₀	20.98 μM Compound: BD	Cytotoxicity against human L02 cells by MTT assay Cytotoxicity against human L02 cells by MTT assay	[PMID: 33964439]
RAW264.7	IC₅₀	1.1 μM Compound: 10	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess assay	[PMID: 31301930]
SMMC-7721	IC₅₀	10.8 μM Compound: 1, PSA	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 25958248]
U-87MG ATCC	IC₅₀	17.34 μM Compound: 12a	Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]

In Vitro

alpha-Hederin (α-Hederin) is cytotoxic and inhibits proliferation in both cel lines at rather low concentrations. alpha-Hederin (α-Hederin)reduces the mitotic activity in treated cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

alpha-Hederin (α-Hederin) has preventive effect on sensitized rats like thymoquinone. It may intervene in miRNA-126 expression, which consequently could interfere with IL-13 secretion pathway leading to a reduction in inflammatory responses^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 27013-91-8
Appearance Solid
Molecular Weight 750.96
Formel C₄₁H₆₆O₁₂
Color White to off-white
SMILES

OC[C@@]1(C)[C@]2([H])CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@@]5([H])C4=CC[C@]3([H])[C@@]2(C)CC[C@@H]1O[C@]6([H])OC[C@H](O)[C@H](O)[C@H]6O[C@@]7([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7
Synonyms

α-Hederin
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All Cell Proliferation/Viability AssayIFCell Imaging/StainingFlow CytometryWB

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Discovery of Natural Compound α-Hederin via Large-Scale Screening as a Targeted JAK/STAT3 Inhibitor for Ovarian Cancer Therapy. [Abstract]

2025 Jul 16:e17278. PMID: 40667652

alpha-Hederin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 16:e17278. [Abstract]

Cell viability of SKOV‐3, OVCAR‐8, and IOSE‐80 cells treated with increasing concentrations of α‐Hederin (2.5, 5, 10, 15, 20 μM) for 24 and 48 h, measured by the CCK‐8 assay.

alpha-Hederin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 16:e17278. [Abstract]

Representative images of EdU staining in cells treated with 0, 5, or 10 µM α‐Hederin for 48 h to assess proliferation.

alpha-Hederin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 16:e17278. [Abstract]

Representative images of colony formation in SKOV‐3, OVCAR‐8, and IOSE‐80 cells treated with α‐Hederin (5, 10 μM).

alpha-Hederin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 16:e17278. [Abstract]

Representative flow cytometry plots of the cell cycle distribution in SKOV‐3 and OVCAR‐8 cells following treatment with 0, 5, or 10 µM α‐Hederin for 48h.

alpha-Hederin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 16:e17278. [Abstract]

Western blot analysis of Cyclin D1, CDK4, and p53 expression in response to α‐Hederin at 5 or 10 µM for 48 h.
Phytomedicine

α-Hederin causes ferroptosis in triple-negative breast cancer through modulating IRF1 to suppress GPX4. [Abstract]

2025 Mar 8:141:156611. PMID: 40153970
Biomedicines

α-Hederin Alleviates Endoplasmic Reticulum Stress by Upregulating TRIM38 Expression, Thereby Inhibiting Hepatic Stellate Cell Activation and Liver Fibrosis. [Abstract]

2026 Apr 5;14(4):829. PMID: 42072369
Naunyn Schmiedebergs Arch Pharmacol

α-Hederin inhibited pancreatic cancer cell malignant progression by inhibiting LDHA-mediated glycolysis. [Abstract]

2025 Feb 19. PMID: 39969605

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (133.16 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3316 mL

6.6581 mL

13.3163 mL

5 mM

0.2663 mL

1.3316 mL

2.6633 mL

10 mM

0.1332 mL

0.6658 mL

1.3316 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wang J, et al. α-Hederin induces the apoptosis of gastric cancer cells accompanied by glutathione decrement and reactive oxygen species generation via activating mitochondrial dependent pathway. Phytother Res. 2020;34(3):601-611. [Content Brief]

[2]. Danloy S et al. Effects of alpha-hederin, a saponin extracted from Hedera helix, on cells cultured in vitro. Planta Med, 1994 Feb, 60(1):45-9. [Content Brief]

[3]. Maryam Fallahi et al. Effect of Alpha-Hederin, the active constituent of Nigella sativa, on miRNA-126, IL-13 mRNA levels and inflammation of lungs in ovalbumin-sensitized male rats. Planta Med, 1994 Feb, 60(1):45-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3316 mL	6.6581 mL	13.3163 mL	33.2907 mL
	5 mM	0.2663 mL	1.3316 mL	2.6633 mL	6.6581 mL
	10 mM	0.1332 mL	0.6658 mL	1.3316 mL	3.3291 mL
	15 mM	0.0888 mL	0.4439 mL	0.8878 mL	2.2194 mL
	20 mM	0.0666 mL	0.3329 mL	0.6658 mL	1.6645 mL
	25 mM	0.0533 mL	0.2663 mL	0.5327 mL	1.3316 mL
	30 mM	0.0444 mL	0.2219 mL	0.4439 mL	1.1097 mL
	40 mM	0.0333 mL	0.1665 mL	0.3329 mL	0.8323 mL
	50 mM	0.0266 mL	0.1332 mL	0.2663 mL	0.6658 mL
	60 mM	0.0222 mL	0.1110 mL	0.2219 mL	0.5548 mL
	80 mM	0.0166 mL	0.0832 mL	0.1665 mL	0.4161 mL
	100 mM	0.0133 mL	0.0666 mL	0.1332 mL	0.3329 mL

Keywords

alpha-Hederin

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

alpha-Hederin

Apoptosis Compound Library

Natural Product Library

Anti-Cancer Compound Library

Glycoside Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Cuproptosis Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) alpha-Hederin

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

alpha-Hederin

Apoptosis Compound Library

Natural Product Library

Anti-Cancer Compound Library

Glycoside Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Cuproptosis Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) alpha-Hederin

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

alpha-Hederin Related Classifications

HY-N0255 Related Classifications